Nanotechnology-Based drug delivery systems for cross-blood-brain barrier pharmacokinetics

Read full text Summarise with VIRAT
Authors: Krzysztof Włodzimierz Zieliński, Tomasz Wieczorek, Magdalena Szymczak
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

While the blood-brain barrier protects the central nervous system with remarkable efficiency that same protection blocks over 98% of small-molecule therapeutics from reaching brain tissue a pharmacokinetic bottleneck that has frustrated neurological drug development for decades [1]. This research compared six nanotechnology-based drug delivery platforms engineered to cross the blood-brain barrier, evaluating their physicochemical properties, in vitro BBB permeability, and in vivo brain distribution in a murine model. We performed the experimental work at two Polish academic institutions between May 2021 and November 2024. Surface-functionalized polymeric nanoparticles, liposomes, solid lipid nanoparticles, gold nanoparticles, PAMAM dendrimers, and exosome-based carriers were loaded with a model fluorescent compound and assessed using an in vitro Transwell BBB model followed by in vivo pharmacokinetic profiling. Transferrin-conjugated PLGA nanoparticles achieved the highest brain accumulation at 8.7% of the administered dose, followed by lactoferrin-functionalized liposomes at 7.3%. A strong inverse correlation emerged between particle size and BBB permeability coefficient (R²=0.64, p

Fields of Study & Subjects

Nanoparticle-Based Drug Delivery Barrier Structure and Function Studies Drug Transport and Resistance Mechanisms

Publication details

Journal / source
International Journal of Pharmacology and Pharmaceutical Sciences
Volume
8
Issue
1
Pages
11–16
Publication date
1 January 2026
Language
EN